aTyr Pharma, Inc. (NASDAQ:LIFE) Weekly Ratings on May 17, 2018

May 17, 2018 - By Karla Blount

aTyr Pharma, Inc. (NASDAQ:LIFE) Corporate Logo

aTyr Pharma, Inc. (NASDAQ:LIFE) Ratings Coverage

A total of 3 analysts rate aTyr Pharma (NASDAQ:LIFE) as follows: 0 “Buy”, 0 “Hold” and 3 “Sell”. Тherefore 0 are bullish. (NASDAQ:LIFE) has 3 ratings reports on May 17, 2018 according to StockzIntelligence. The company rating was downgraded by JP Morgan on Wednesday, February 14. On Wednesday, February 14 the company was downgraded by J.P. Morgan. On Tuesday, May 15 the rating was downgraded by Citigroup to “Sell”. Listed here are aTyr Pharma, Inc. (NASDAQ:LIFE) PTs and latest ratings.

15/05/2018 Broker: Citigroup Rating: Sell New Target: $1.0000 Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade

LIFE is touching $0.95 during the last trading session, after increased 11.20%.aTyr Pharma, Inc. is downtrending after having declined 19.01% since May 17, 2017. LIFE has 1.04 million volume or 681.58% up from normal. The stock underperformed the S&P500 by 30.56%.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases.The firm is valued at $28.17 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy.Last it reported negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.

For more aTyr Pharma, Inc. (NASDAQ:LIFE) news announced recently go to: Benzinga.com, Nasdaq.com, Seekingalpha.com, Benzinga.com or Nasdaq.com. The titles are as follows: “Benzinga Pro’s 5 Stocks To Watch Today” announced on May 17, 2018, “aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 …” on May 17, 2018, “Premarket analyst action – healthcare” with a publish date: May 15, 2018, “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” and the last “Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide” with publication date: May 14, 2018.

aTyr Pharma, Inc. (NASDAQ:LIFE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.